Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another reverse split seems inevitable. The cash infusion, hopefully, will hasten the company to eventually reach a Phase III status on Tusp sometime during my lifetime.
If efficacy is as superior as I have read over time, then maybe we are at point where a modest price cut could turn the tables. Can anyone venture a guess as to what the "market will bear", price-wise, to include more insurance coverage?
True to form, no revenue projections for the foreseeable future has relegated APTO to a pre-reverse split value of $.05.
I scratch my head over the part of the commentary related to safety profiles. Three years into Aurora, there is supposedly no change in the safety profiles while the efficacy profiles have proven to be solid. So shouldn't the safety profiles be amended so the base treatment can be expanded?
The "2s", given increasing revenues and a stock buy-back, is a bit of lunge at this point. I can remember a few years ago when the stock traded at this level without an FDA approval.
Asking ourselves the obvious question, is APTO any closer to commercialization of product? My answer is NO, and I imagine yet another reverse split will be on the horizon in a year. Dilutions will take the stock below $1.00 again without any announcements of a stand-alone Phase 3 test anywhere......IMHO.
When and where is this month's annual meeting of shareholders?
This is what happens after reverse splits when there is no perceived improvement to the business plan........let alone revenues
Is anyone surprised? The company has a perpetual green light to nowhere.
.....which means the "Black Box" should be eliminated?
It appears to be just "trading range" trading that has been going on for a long time.
Yahoo's recent commentaries informed us about welcomed additions to the BOD. One of the newbies is Dr. Robert Foster, the person who actually discovered Voclosporin. It appears that the new members have a lot of experience and corporate clout. The text referred to their drive to maximize shareholder value and get VOCS where it needs to be in the marketplace. I get the impressions that, while Peter retained his official position, his own clout has been diminished. So let's see where this new development goes.
It's great news.....but......will the company forge ahead with the 160 mg dose that works and actually work toward a Phase III? No word on Lux.
Yahoo Finance's recent coverage may be the best news AUPH has received since initial approval. VOCS should be looking at more wide-spread use now, and whatever warning labels are left should be on their way to removal.
For sure.........industry wide, however, institutions look at burn rates, delays in test results, and the prospect of higher borrowing costs. Companies with decent balance sheets get caught up in a "guilt by association" scenario when times are tough for the industry.
Lengthy interest rate hikes always take their toll on biotech.
Take it with the proverbial grain of salt. These tactics happen all the time in pennydom.
This Board consists of seasoned physicians and technical people with really good reputations. I would imagine they have their own personal stakes in this venture and know where the risks are....including the risks to their own reputations.
22 cents pre-reverse split. This phenomenon is not acute to APTO. It happens to any/all companies who effect a reverse split to try and retain the NASDAQ listing going forward but then do not have the improvements to the business model to support the elevated stock price.
The timing of the Goldman purchase and the announcement of new Directors and Chairman is interesting, to say the least. The people, at least, seem to be better qualified than anyone else on the current roster.
Positive dosage results were there, but the company kept getting greedy looking for more. I never understood that motivation.
Yes.......an okay to begin Phase III trials with a clear path to FDA evaluation. Right now, the pre-split price has dropped to .30.
I guess so....but maybe not at the same time?
For the sake of argument. PG's history includes time spent at Centocor, Medimmune, and Boehringer. All three companies made a bunch of money for shareholders. None of the three companies had necessarily smooth sailing along the way to stardom. My biggest hope is that further study results remain so positive that the black box warning can be repealed. Proving robust stats for even milder cases won't hurt either.
It's trading at 40 cents pre-split............nothing to write home about
Three years ago, the 80 ml dose could have become a "benchmark" toward approval....but.....NO.........
The market makers are creating a vacuum for this stock. That being said, there has to be something desperately wrong here justifying current selling of this magnitude.
Any comments about this shareholder update coming up on a Saturday?
Those media-created critical spews about soldiers have been long debunked. The Secret Service, however, did spill a few beans over the years about anti-military comments from Madame Hillary.
Historically, a reverse split is the beginning of the death spiral if the company cannot improve its lot in the marketplace. Advanced testing, more collaboration with partners, a merger, and/or eventual commercialization will help stabilize Aptose's position and stock price. . Should the company continue to just spin its wheels, however, the post-split higher price will not hold up, and the stock eventually will head back to that $1.00 level. "Light At The End Of The Tunnel" is what post-split shareholders need to see.
I always have appreciated this board. Think about it. The differences we discuss here are free and open as compared to the woke cancel culture with which we have to deal every day. Either side, on occasion, may have missed a few details over the years but, like right now, the cards are on the table and awaiting the next hand to play. We know where the issues stand, and we're working on our sense of patience.. Each one of us has had a role.
I just finished listening to the commentary twice. The combination therapies seem to be working in tests every which way, a good thing. What continues to plague the process, IMHO, is not finding advanced testing avenues that lead to eventual commercialization. Pick one of the dosage sizes that works, and Go For It.
Comments are appreciated, Jess. You have been a proponent of maintaining the current direction, yet a few major shareholders have made it clear that they believe shareholders in general have been short-changed.
This meeting was OVER in about 10 minutes. The auditors were approved, but the increase in authorized shares also was denied. The message to management is loud and clear.
This meeting was OVER in about 10 minutes. The auditors were approved, but the increase in authorized shares also was turned denied. The message to management is loud and clear.
Management and all other issues aside, this stock continues to hit a brick wall at $12.00.
Thien what else?......ultimately there is NO future without revenue or a profitable merger. Maybe in the very short term the company can sustain its stock price, after the reverse split, by actually entering a Phase III testing portal. That momentum might keep the stock above $1.00 for a while......but not forever.
The stock has dropped from the .60 area to the .49 area. That means, after the reverse split, the stock will trade lower automatically from where it traded a few short weeks ago. The long term ramifications are the same for APTO as they are for any company effecting a reverse split. Usually, low priced stocks are given a short term shot in the arm by maintaining their NASDAQ status above $1.00. The problem is the prospect for future revenues. This company can't even decide which dosage to take to Phase III. The longer it drags out and revenues are delayed, the lower the stock price will be.....yes even after the reverse split. I have seen only two reverse splits work out for shareholders over a 30+ year span.
So....when and where is the 2023 shareholder meeting?